Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC

WEDNESDAY, Aug. 3, 2022 -- For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX), according to...